Include All CSL Behring Country Sites


Media Contacts:


Sharon McHale
Mobile: +44 (0) 7810 757030

United States

Polina Miklush   
Phone: +1 212 583 2793

Asia Pacific

Jemimah Pentland
Phone: +61 (0) 412 635 483

News Releases

Seqirus receives FDA approval for AFLURIA® QUADRIVALENT (Influenza Vaccine) for people 18 years of age and older
Seqirus announced today that the US Food and Drug Administration (FDA) has approved AFLURIA® QUADRIVALENT (Influenza Vaccine) for use in persons 18 years of age and older. AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Both AFLURIA QUADRIVALENT and AFLURIA® (Influenza Vaccine), are available in the US for the 2016-2017 influenza season. More.

Seqirus Presents Integrated Analyses for Trivalent Adjuvanted Seasonal Influenza Vaccine for Young Children
Seqirus today announced results of two data integrated analyses from six randomized clinical trials evaluating the safety and immunogenicity of its trivalent MF59-adjuvanted seasonal influenza vaccine in children aged six months to less than six years. 1,2 More.

Seqirus is first-to-market with shipment of seasonal influenza vaccines to the US for the 2016-2017 season
Seqirus announced today that it has begun shipment of its portfolio of influenza vaccines to customers in the US market for the 2016-2017 season. More.

Seqirus donates vaccines to Fiji to alleviate increase in influenza
Seqirus today announced the donation of 20,000 doses of seasonal influenza vaccine to the people of Fiji in order to help alleviate a spike in cases of severe influenza. More.

Seqirus receives FDA approval for FLUCELVAX QUADRIVALENT™ (Influenza Vaccine) for people four years of age and older
“We are pleased to offer FLUCELVAX QUADRIVALENT, which is produced at our full-scale cell culture influenza vaccine manufacturing facility in North Carolina, to our valued customers during the 2016-2017 flu season.” More.

Seqirus Honored with National Award for Outstanding Efforts in Influenza Prevention
Seqirus announced today that the National Adult and Influenza Immunization Summit (NAIIS) awarded the organization with the 2016 Immunization Excellence Award for best Corporate Campaign. The accolade recognizes Seqirus’ creative and collaborative efforts to improve vaccination awareness and rates during the 2015-16 influenza season. The award was presented yesterday during the NAIIS Summit in Atlanta, Georgia. More.

Seqirus Commemorates 100 Years of Parent Company, CSL,
Delivering on its Promise to Develop Innovative Therapies

Seqirus today commemorated with parent company, CSL Limited, 100 years of developing and delivering innovative therapies, including influenza vaccines and treatments that protect and save lives of people with serious and chronic medical conditions. To mark this milestone, CSL announced a A$25 million R&D Fellowship program for early stage and translational research. More.

Joint media release from Invest Liverpool, the Mayor of Liverpool and Seqirus

Today the world’s no. 2 influenza vaccine provider, Seqirus, announced a £22.1m investment for its UK manufacturing site in Liverpool. More.

CSL completes Novartis influenza vaccine acquisition in Germany
CSL Limited (ASX:CSL; USOTC: CSLLY) today announced the legal close of the acquisition of the Novartis influenza vaccine business in Germany. This transaction follows CSL’s staged acquisition of Novartis’ global influenza vaccine business on 31 July 2015. In Germany, the transaction has been cleared by regulators and local employment councils. More.